NASDAQ
Ionis Pharmaceuticals, Inc. (IONS)
♥ 623 Thanks from members
Ionis Pharmaceuticals faces severe near-term volatility following a Phase 3 ATTR cardiomyopathy trial miss with AstraZeneca, yet retains robust underlying fundamentals, highlighted by strong early sales momentum for TRYNGOLZA and $1.9B to $2.1B in liquidity supporting its 2028 breakeven path.